(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma

Adjuvant Tebentafusp in High Risk Ocular Melanoma

NCT06246149 ·Status: RECRUITING ·Phase: PHASE3

Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions

NCT03947385 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

A Study to Compare Nivolumab Drug Product Process D to Nivolumab Drug Product Process C in Participants With Stage IIIa/b/c/d or Stage IV Melanoma After Complete Resection

NCT03980314 ·Status: COMPLETED ·Phase: PHASE1

Study of Pembrolizumab (MK-3475) Versus Placebo After Complete Resection of High-Risk Stage III Melanoma (MK-3475-054/1325-MG/KEYNOTE-054)

NCT02362594 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Intratumoral CAVATAK (CVA21) and Ipilimumab in Patients With Advanced Melanoma (VLA-013 MITCI)

NCT02307149 ·Status: COMPLETED ·Phase: PHASE1

An Observational Study of Adjuvant (Post-surgery) Therapy With Nivolumab for Resected (Completely Removed) Melanoma in Australia

NCT04146324 ·Status: COMPLETED

Durvalumab (MEDI4736) Plus Cediranib in Patients With Metastatic Uveal Melanoma

NCT04184518 ·Status: WITHDRAWN ·Phase: PHASE2

Lenalidomide (Revlimid) to Treat Advanced Ocular Melanoma

NCT00109005 ·Status: COMPLETED ·Phase: PHASE2

Neoadjuvant Combination Therapy With Ipilimumab and HighDose IFN-α2b for Melanoma

NCT01608594 ·Status: COMPLETED ·Phase: PHASE1

A National Phase IV Study With Ipilimumab for Patients With Advanced Malignant Melanoma.

NCT02068196 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4

Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advance Melanoma (MK-7902-003/E7080-G000-312/LEAP-003)

NCT03820986 ·Status: COMPLETED ·Phase: PHASE3

Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma

NCT00324155 ·Status: COMPLETED ·Phase: PHASE3

A Study to Compare the Administration of Pembrolizumab After Surgery Versus Administration Both Before and After Surgery for High-Risk Melanoma

NCT03698019 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

A Randomised Phase II Study of Roginolisib in Patients With Advanced/Metastatic Uveal Melanoma

NCT06717126 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Study of Adjuvant Ipilimumab and Nivolumab in Subjects With High-risk Ocular Melanoma

NCT03528408 ·Status: UNKNOWN ·Phase: PHASE2

Patient Experience and Quality of Life During the Surveillance Phase of Uveal Melanoma: A Prospective Multi-method Study

NCT06073548 ·Status: NOT_YET_RECRUITING

Ipilimumab and Nivolumab With Immunoembolization in Treating Participants With Metastatic Uveal Melanoma in the Liver

NCT03472586 ·Status: COMPLETED ·Phase: PHASE2

RAD001 Plus Bevacizumab in Metastatic Melanoma

NCT00591734 ·Status: COMPLETED ·Phase: PHASE2

Melphalan Chemoreduction for Ocular Melanoma

NCT05893654 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE1/PHASE2

Uveal Melanoma and Brachytheraphy: Long-term Outcomes.

NCT04577742 ·Status: COMPLETED

A Phase II Trial of Neoadjuvant Treatment With PD-1 Inhibition (Nivolumab) With or Without IDO Inhibition (BMS-986205) and With or Without CTLA-4 Inhibition (Ipilimumab) in Resectable Stage III or IV Melanoma

NCT04007588 ·Status: WITHDRAWN ·Phase: PHASE2

Effects of Anti-PD1 Adjuvant Checkpoint Blockade Immunotherapy on Atypical/Dysplastic Nevi

NCT06599619 ·Status: RECRUITING

Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma (CheckMate 064)

NCT01783938 ·Status: COMPLETED ·Phase: PHASE2

A Study of Ceralasertib Monotherapy and Ceralasertib Plus Durvalumab in Patients With Melanoma and Resistance to PD-(L)1 Inhibition

NCT05061134 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Real-world Outcomes Among Patients With Melanoma Treated With Neoadjuvant Nivolumab+Relatlimab or Nivolumab+Ipilimumab

NCT07091695 ·Status: COMPLETED